Pharmaceutical Technology

JULY 28, 2022

Many of the mainstay drugs for the treatment of moderate to severely active UC, such as anti-tumour necrosis factor (anti-TNF) agents like infliximab, target inflammatory mediators that are dysregulated in this condition. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 20, 2023

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Drugs 147

Drugs Medicine Marketing Development 147

Pharmaceutical Technology

JANUARY 2, 2023

The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc.

Drugs 100

Drugs Production Manufacturing Development 100

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 14, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

Drug Delivery 147

Drug Delivery Drugs Drug Delivery Systems FDA Approval 147

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 10, 2023

Lebanon’s ongoing economic crisis and changes in pricing strategies have caused monumental price hikes that impact market access. In Lebanon, the battle for access to medicines rages on and is further heightened by dramatic decreases to the healthcare budget last year. Additionally, Lebanon relies on foreign currency for 80% of drugs.

Marketing 130

Marketing Branding Manufacturing Medicine 130

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Production 162

Production Regulation Clinical Trials Clinical Trials 162

Pharmaceutical Technology

NOVEMBER 23, 2022

Innovations in biotechnology are advancing the biopharmaceutical market, enabling the treatment of complex diseases with next-generation therapeutics synthesised or extracted from a biological source. The city is also home to two research hospitals, Hamilton Health Sciences and St Joseph’s Healthcare Hamilton.

Marketing 130

Marketing Gene Therapy Life Science Manufacturing 130

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). The drug candidate is administered through subcutaneous route.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

FDA Approval 130

FDA Approval Production Compliance Clinical Trials 130

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

XTalks

APRIL 19, 2024

Avicenna.AI , a leading medical imaging AI company, has received US Food and Drug Administration (FDA) 510(k) clearance for two of its AI-based tools, CINA-iPE and CINA-ASPECTS, which are designed to enhance the diagnosis and assessment of pulmonary embolism and stroke severity, respectively, via CT scans. percent and 24.2 percent and 24.2

Marketing 52

Marketing Radiology Development Manufacturing 52

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. Telehealth is especially important for improving healthcare accessibility in rural regions. Pharmacy chains have become the backbone for providing infrastructure to roll out telehealth services.

Dermatology 130

Dermatology Pharmacy Branding Marketing 130

World of DTC Marketing

AUGUST 12, 2022

PhRMA is lying to protect its profits, and the lies have reached a new height as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act. Of course, the drug industry warns that any price negotiation will kill innovation. First, let’s clarify how the bill saves taxpayers billions.

Drugs 255

Drugs Research Development Regulation 255

XTalks

FEBRUARY 5, 2024

GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK said it has secured about two-thirds share of the US market where nearly all of Arexvy’s sales were recorded. In addition to promoting uptake in the US, GSK and Pfizer are also focused on expanding in the global market.

Vaccination 59

Vaccination Vaccine Marketing Sales 59

Pharmaceutical Technology

DECEMBER 5, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has also since granted the Great Britain marketing authorisation of Lupkynis to treat adults with active LN. Notably, Lupkynis is the first oral therapy approved by the US Food and Drug Administration (FDA) and EC for the treatment of active LN.

FDA Approval 147

FDA Approval Compliance Trials Marketing 147

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Life Science 162

Pharmaceutical Technology

AUGUST 12, 2022

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. million people in the UK and 2.7

Clinical Trials 354

Clinical Trials Clinical Trials Marketing Development 354

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality. A new frontier in cancer research. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Gevokizumab’s valuation in its risk-adjusted NPV model (rNPV).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. billion by 2028.

Sales 111

Sales Medicine Drugs Marketing 111

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. It said the drug was the first to treat the underlying mechanism in Alzheimer’s rather than addressing symptoms.

Drugs 98

Drugs Marketing FDA Approval Trials 98

Pharmaceutical Technology

JULY 29, 2022

Once new vaccines for the Omicron variant are approved, they will partly make up for the waning interest in older Covid boosters in developed markets. This data has been shared with regulators, including the US Food and Drug Administration (FDA), and a request for US Emergency Use Authorisation (EUA) is planned.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

XTalks

OCTOBER 27, 2023

A new AI tool that can help identify and quantify brain structures from MRI scans has been cleared by the US Food and Drug Administration (FDA). With the FDA clearance, VUNO said it intends to boost its sales and marketing efforts towards US medical institutions. The integration of AI technology in medical imaging is growing rapidly.

Sales 69

Sales Clinical Research Marketing Production 69

Pharmaceutical Technology

DECEMBER 27, 2022

The Covid-19 pandemic pushed most markets into free fall, leading to increased wariness for completing large mergers and acquisitions (M&As) in the pharmaceutical sector. There's an absolute market demand.” On December 12, Amgen said it will acquire the rare disease biotech in a $27.8 There's no other way around it,” says Baral.

Life Science 130

Life Science Marketing Manufacturing Contract Manufacturing 130

XTalks

OCTOBER 13, 2023

Zürich-based med tech startup Sleepiz AG has been granted US Food and Drug Administration (FDA) Class II 510(k) clearance for its bedside device that measures vital signs during sleep. The signals are then transformed by proprietary artificial intelligence (AI) into actionable data for healthcare professionals.

Clinical Trials 45

Clinical Trials Clinical Trials Drugs Trials 45

Pharmaceutical Technology

OCTOBER 5, 2022

Technology is advancing the possibilities of healthcare treatments, from the development of innovative new drugs to freeing up time for doctors thanks to monitoring devices for patients with conditions such as diabetes and high blood pressure. between 2017 and 2021, peaking at 453 deals in 2020, according to GlobalData figures.

Life Science 130

Life Science Development Medicine Doctors 130

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. Production facilities highlight differences in drug focus. These solid dose sites are based in Austria, Germany, Poland and India.

Manufacturing 162

Manufacturing Drugs Branding Sales 162

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). GlobalData is the parent company of Pharmaceutical Technology.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

FEBRUARY 1, 2023

As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody FDA Approval 162